Inozyme Pharma Inc (INZY)
3.42
-0.13
(-3.66%)
USD |
NASDAQ |
Nov 14, 16:00
3.50
+0.08
(+2.34%)
After-Hours: 20:00
Inozyme Pharma Net Income (Quarterly): -24.57M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | -24.57M |
June 30, 2024 | -27.03M |
March 31, 2024 | -23.35M |
December 31, 2023 | -21.54M |
September 30, 2023 | -16.64M |
June 30, 2023 | -15.58M |
March 31, 2023 | -17.40M |
December 31, 2022 | -18.54M |
September 30, 2022 | -16.37M |
June 30, 2022 | -15.26M |
March 31, 2022 | -16.88M |
December 31, 2021 | -18.75M |
Date | Value |
---|---|
September 30, 2021 | -14.28M |
June 30, 2021 | -12.54M |
March 31, 2021 | -11.05M |
December 31, 2020 | -11.12M |
September 30, 2020 | -28.10M |
June 30, 2020 | -9.473M |
March 31, 2020 | -7.738M |
December 31, 2019 | -6.544M |
September 30, 2019 | -4.035M |
June 30, 2019 | -4.173M |
March 31, 2019 | -4.971M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-28.10M
Minimum
Sep 2020
-6.544M
Maximum
Dec 2019
-16.64M
Average
-16.50M
Median
Net Income (Quarterly) Benchmarks
Tango Therapeutics Inc | -29.17M |
CEL-SCI Corp | -6.857M |
AIM ImmunoTech Inc | -1.836M |
IGC Pharma Inc | -2.378M |
NovaBay Pharmaceuticals Inc | -1.212M |
Net Income (Quarterly) Related Metrics
Total Expenses (Quarterly) | 24.85M |
EPS Diluted (Quarterly) | -0.39 |
Enterprise Value | 142.09M |
Earnings Yield | -45.61% |